Recommended reading in population pharmacokinetic pharmacodynamics

AAPS Journal

Volumn 7, Issue 2, 2005, Pages

  Bonate, Peter L ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

First order approximation; Influential articles; NONMEM; Review

Indexed keywords

ALPRAZOLAM; DIGOXIN; DOCETAXEL; ENOXAPARIN; FLUCYTOSINE; IMIPRAMINE; OROSOMUCOID; PHENYTOIN;

ANALYTICAL ERROR; ARTICLE; BACTERIAL INFECTION; BLEEDING; BRAIN HEMORRHAGE; CANDIDIASIS; COVARIANCE; CRYPTOCOCCUS NEOFORMANS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RESEARCH; FREQUENCY ANALYSIS; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEARNING; LITERATURE; MATHEMATICAL ANALYSIS; PHARMACODYNAMICS; POPULATION MODEL; PUBLICATION; READING; SEIZURE; SKILL; SOLID TUMOR; STATISTICAL ANALYSIS; STEADY STATE; URINARY EXCRETION; VALIDATION PROCESS;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; PERIODICALS; PHARMACOKINETICS; READING;

EID: 30544454555     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070237     Document Type: Article

References (42)

1. Sheiner LB, Rosenberg B, Marathe V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977;5:445-479.
2. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm. 1981;9:635-651.
3. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine pharmacokinetic data. J Pharmacokinet Biopharm. 1982;11:303-319.
4. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980;8:553-571.
5. Peck CC, Beal SL, Sheiner LB, Nichols AI. Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data. J Pharmacokinet Biopharm. 1984;12:545-558.
6. Sheiner LB, Beal SL. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm. 1985;13:185-201.
7. Vozeh S, Katz G, Steiner V, Follath F. Population pharmacokinetic parameters in patients treated with oral mexiletine. Eur J Clin Pharmacol. 1982;23:445-451.
8. Grasela TH, Sheiner LB. Population pharmacokinetics of procainamide from routine clinical data. Clin Pharmacokinet. 1984;9:545-554.
9. Grasela T, Donn SM. Neonatal population pharmacokinetics for phenobarbital derived from routine clinical data. Dev Pharmacol Ther. 1985;8:374-383.
10. Grasela TH, Antal EJ, Ereshefsky L, Wells BG, Evans RL Smith RB. An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction. Clin Pharmacol Ther. 1987;42:433-441.
11. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci. 2002;4:E27.
12. Maitre PO, Buhrer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm. 1991;19:377-384.
13. Mandema J, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511-528.
14. Hastie TJ, Tibshirani RJ. Generalized Additive Models. New York: Chapman and Hall, 1990.
15. Bruno R, Vivier N, Vergniol JC, DePhillips SL, Montay G, Sheiner LB. A population model for docetaxel (Taxotere®): model building and validation. J Pharmacokinet Biopharm. 1996;24:153-172.
16. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735-750.
17. Laporte-Simitsidis S, Girard P, Mismetti P, Chabaud S, Decousus H, Boissel JP. Inter-study variability in population pharmacokinetic analysis: when and how to estimate it? J Pharm Sci. 2000;89:155-166.
18. Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J Pharmacokinet Biopharm. 1994;22:165-176.
19. Verbeke G, Molenberghs G. Linear Mixed Models in Practice: A SAS-Oriented Approach. New York: Springer Verlag; 1997.
20. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231-252.
21. Wahlby U, Bouw MR, Jonsson EN, Karlsson MO. Assessment of type I error rates for statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn. 2002;29:251-269.
22. Stram DO, Lee JW. Variance components testing in the longitudinal mixed effects model. Biometrics. 1994;50:1171-1177.
23. Pinheiro JC, Bates DM. Mixed-Effect Models in S and S-Plus. New York: Springer Verlag; 2000.
24. Aarons L, Balant LP, Mentre F, Morselli PL, Rowland M Steimer J-L, Vozeh S. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol. 1996;49:251-254.
25. Kowalski K, Hutmacher MM. Design evaluation for a population pharmacokinetic study using clinical trial simulation: a case study. Stat Med. 2001;20:75-91.
26. Lee PID. Design and power of a population pharmacokinetic study. Pharm Res. 2001;18:75-82.
27. Green D, Duffull SB. Prospective evaluation of a D-optimal designed population pharmacokinetic study. J Pharmacokinet Pharmacodyn. 2003;30:145-161.
28. Duffull SB, Retout S, Mentre F. The use of simulated annealing for finding optimal population designs. Comput Methods Programs Biomed. 2002;69:25-35.
29. Karlsson MO, Jonsson EN, Wiltse CG, Wade JR. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998;26:207-246.
30. Bonate PL. The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res. 1999;16:709-717.
31. Hartford A, Davidian M. Consequences of misspecifying assumptions in nonlinear mixed effects models. Comp Stat Data Anal. 2000;34:139-164.
32. Ette EI, Williams PJ, Kim YH, Lane JR, Liu M-J, Capparelli EV. Model appropriateness and pharmacokinetic modeling. J Clin Pharmacol. 2003;43:610-623.
33. Bruno R, Baille P, Retout S, Vivier N, Veyrat-Follet C Sanderlink G-J, Becker R, Antman EM. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol. 2003;56:407-414.
34. Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol. 2003;43:698-710.
35. Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30:329-332.
36. Grasmader K, Verwohlt PL, Kuhn K-U, Dragicevic A, von Widdern O, Zobel A, Hiemke C, Rietschel M, Maier W, Jaehde U, Rao ML. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol. 2004;60:473-480.
37. Beal SL, Sheiner LB. Methodology of population pharmacokinetics. In: Garrett ER, Hirtz JL, eds. Drug Fate and Metabolism: Methods and Techniques, Vol. 5. New York: Marcel Dekker, Inc; 1985;135-183.
38. Sheiner LB, Ludden TM. Population pharmacokinetics/pharmacodynamics. Annu Rev Pharmacol Toxicol. 1992;32:185-209.
39. Tett S, Holford NHG, McLachlan AJ. Population pharmacokinetics and pharmacodynamics: an underutilized resource. Drug Inf J. 1998;32:693-710.
40. Davidian M, Giltinan DM. Nonlinear Models for Repeated Measures Data. New York: Chapman and Hall; 1995.
41. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer-Verlag; 2000.
42. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry. Population Pharmacokinetics. Washington, DC: Food and Drug Administration; 1999.